Latest news with #Guardant360Tissue
Yahoo
21-05-2025
- Business
- Yahoo
Guardant Health (GH) introduces IHC Solid Tumor Testing to its Portfolio
On May 21, Guardant Health, Inc. (NASDAQ:GH) announced adding a full suite of immunohistochemistry to its portfolio of tumor molecular profiling tests. This addition will help oncologists identify the subtypes of tumors, thereby enabling them to match cancer patients with targeted therapies. Analysing a blood sample, a technician in a lab coat using precision diagnostic equipment. Guardant Health, Inc. (NASDAQ:GH) is a precision oncology company specializing in advanced blood and tissue tests, real-world data, and artificial intelligence analytics. Immunohistochemistry testing, also known as IHC, is a specialized staining technique used to detect specific proteins called tumor biomarkers within tissue samples. These biomarkers reveal important characteristics of a tumor that help doctors determine the most appropriate targeted cancer therapies. The testing suite introduced by Guardant Health, Inc. (NASDAQ:GH) covers various biomarkers, including HER2, MMR, PD-L1, c-MET, ER, PR, Ki-67, CLDN18, and FOLR1. Helmy Eltoukhy, chairman and co-CEO of the company, said: 'The information about tumor characteristics garnered from advanced IHC testing will complement the multidimensional insights we are currently providing to oncologists through our recently introduced Guardant360 Tissue multi-omic tumor profiling test.' To put things into perspective, Guardant Health, Inc. (NASDAQ:GH) launched its upgraded version of Guardant360 Tissue, which is the first of its kind multi-omic CGP product with expanded genomic and epigenomic breadth. These are significant developments as Oncology segments contribute more than 50% to the total revenue. During the fiscal first quarter of 2025, the Oncology revenue contributed $150.6 million to the total revenue of $203.5 million, driven by 59,000 oncology tests. While we acknowledge the potential of GH as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than GH and that has 100x upside potential, check out our report about the . READ NEXT: and . Disclosure: None Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21-05-2025
- Business
- Yahoo
Guardant Health (GH) introduces IHC Solid Tumor Testing to its Portfolio
On May 21, Guardant Health, Inc. (NASDAQ:GH) announced adding a full suite of immunohistochemistry to its portfolio of tumor molecular profiling tests. This addition will help oncologists identify the subtypes of tumors, thereby enabling them to match cancer patients with targeted therapies. Analysing a blood sample, a technician in a lab coat using precision diagnostic equipment. Guardant Health, Inc. (NASDAQ:GH) is a precision oncology company specializing in advanced blood and tissue tests, real-world data, and artificial intelligence analytics. Immunohistochemistry testing, also known as IHC, is a specialized staining technique used to detect specific proteins called tumor biomarkers within tissue samples. These biomarkers reveal important characteristics of a tumor that help doctors determine the most appropriate targeted cancer therapies. The testing suite introduced by Guardant Health, Inc. (NASDAQ:GH) covers various biomarkers, including HER2, MMR, PD-L1, c-MET, ER, PR, Ki-67, CLDN18, and FOLR1. Helmy Eltoukhy, chairman and co-CEO of the company, said: 'The information about tumor characteristics garnered from advanced IHC testing will complement the multidimensional insights we are currently providing to oncologists through our recently introduced Guardant360 Tissue multi-omic tumor profiling test.' To put things into perspective, Guardant Health, Inc. (NASDAQ:GH) launched its upgraded version of Guardant360 Tissue, which is the first of its kind multi-omic CGP product with expanded genomic and epigenomic breadth. These are significant developments as Oncology segments contribute more than 50% to the total revenue. During the fiscal first quarter of 2025, the Oncology revenue contributed $150.6 million to the total revenue of $203.5 million, driven by 59,000 oncology tests. While we acknowledge the potential of GH as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than GH and that has 100x upside potential, check out our report about the . READ NEXT: and . Disclosure: None
Associated Press
28-04-2025
- Business
- Associated Press
Guardant Health Launches Guardant360 Tissue, First Tissue Molecular Profiling Test with Comprehensive Multiomic Analysis to Provide a More Complete View of Cancer
PALO ALTO, Calif.--(BUSINESS WIRE)--Apr 28, 2025-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the launch of Guardant360 ® Tissue, the first molecular profiling test for tumor tissue that incorporates comprehensive multiomics analysis—including DNA, RNA, AI-powered PD-L1 and exome-wide methylation data—to provide researchers and cancer care teams with a more comprehensive view of cancer. Powered by the Guardant Infinity™ smart liquid biopsy platform, the advanced Guardant360 Tissue test enables insights beyond what can typically be found using tests that do not incorporate comprehensive analysis of epigenetics. These insights can apply to important classes of therapeutics, such as PARP-inhibitors and immunotherapies, as well as important new classes of therapies in late-stage development. The test also enables classification and subtyping of each individual tumor at a much higher resolution, potentially enabling a new era of precision oncology research and clinical applications. In addition, since Guardant360 Tissue is built on the smart liquid biopsy platform, it requires 92% less tissue surface area for analysis than the industry norm. In a real-world assessment, more than 50% of tumor tissue samples from patients failed to meet the surface area requirement – meaning those patients couldn't qualify for testing. 1 The Guardant360 Tissue test allows biopharmaceutical researchers and healthcare providers to successfully analyze tissue samples with 40% fewer slides and thus test more patients using less precious tissue. 'Guardant360 Tissue establishes a new standard in tissue molecular profiling, enabling a much broader dimension of insights to provide biopharma and oncologists with an unprecedented view of each individual tumor,' said Helmy Eltoukhy, Guardant Health chairman and co-CEO. 'And because it is built on our smart liquid biopsy platform, the test will leverage the countless multiomic applications that are being built around our Guardant360 liquid biopsy ecosystem. We believe this synergy will provide a new level of clinical actionability and improved patient outcomes across our entire product portfolio.' For biopharmaceutical partners, the Guardant360 Tissue test offers differentiated molecular profiling by its extensive and unique genomic and epigenomic offering. The test analyzes 742 DNA genes and fusions in 367 RNA genes, with the ability to provide exome-wide analysis of the tumor methylome. Test results are available in less than two weeks. Guardant360 Tissue is covered by Medicare for eligible patients. About Guardant Health Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit and follow the company on LinkedIn, X (Twitter) and Facebook. Forward-Looking Statements This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health's liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health's financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operation' and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2024, and in its other reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health's views as of any date subsequent to the date of this press release. References 1. Tomlins, Scott A et al. Real-World Performance of a Comprehensive Genomic Profiling Test Optimized for Small Tumor Samples. JCO Precision Oncology. 2021. View source version on CONTACT: Investor Contact: Zarak Khurshid [email protected] Contact: Michael Weist [email protected] +1 317-371-0035 KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA INDUSTRY KEYWORD: ONCOLOGY HEALTH GENETICS CLINICAL TRIALS PHARMACEUTICAL BIOTECHNOLOGY SOURCE: Guardant Health, Inc. Copyright Business Wire 2025. PUB: 04/28/2025 08:05 AM/DISC: 04/28/2025 08:04 AM
